Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
114.90
-0.38 (-0.33%)
Streaming Delayed Price
Updated: 12:28 PM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vaxcyte Inc
< Previous
1
2
3
Next >
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
Via
Benzinga
Peering Into Vaxcyte's Recent Short Interest
August 27, 2024
Via
Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
May 08, 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Recap: Vaxcyte Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
September 03, 2024
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Via
Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Via
Investor's Business Daily
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
March 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Preview: Vaxcyte's Earnings
February 24, 2023
Via
Benzinga
Expert Ratings for Vaxcyte
January 03, 2023
Via
Benzinga
Why Shares of Vaxcyte Rose 110.7% This Week
October 29, 2022
The company released early data for a promising pneumonia vaccine.
Via
The Motley Fool
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
January 05, 2024
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Via
Benzinga
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
December 07, 2023
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).
Via
Benzinga
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
April 20, 2023
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...
Via
Benzinga
Why Vaxcyte Stock Is Sliding After Hours
April 17, 2023
Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a
Via
Benzinga
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
January 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
April 18, 2023
Via
Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
January 03, 2023
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market...
Via
Benzinga
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
October 26, 2022
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
December 16, 2022
Via
Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
October 25, 2022
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Upgrades
Via
Benzinga
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
October 24, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday.
Via
Benzinga
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
October 25, 2022
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.
Via
Benzinga
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
October 24, 2022
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.